Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Otto

Showing results (151-160 of 155) with videos related to

Pageof 16
Sort By:
You have reached the last page of results.This site can display upto 155 results.
Nature Genetics|November 1, 2001
Mutation of BSND causes Bartter syndrome with sensorineural deafness and kidney failureR Birkenhäger, E Otto, M J Schürmann, et al.
Frontiers in Immunology|February 9, 2026
POLB 001, a p38 MAPK inhibitor, decreases local and systemic inflammatory responses following <i>in vivo</i> LPS administration in healthy volunteers: a randomised, double-blind, placebo-controlled studyDigna T de Bruin, Manon A A Jansen, Diana R Pereira, et al.
Cell Reports|November 2, 2022
Arid1a loss potentiates pancreatic β-cell regeneration through activation of EGF signalingCemre Celen, Jen-Chieh Chuang, Shunli Shen, et al.
Journal of Psychopharmacology (Oxford, England)|October 16, 2025
A novel psychedelic 5-HT<sub>2A</sub> receptor agonist GM-2505: The pharmacokinetic, safety, and pharmacodynamic profile from a randomized trial healthy volunteerGerard J Marek, Soma Makai-Bölöni, Daniel Umbricht, et al.
Nature Genetics|January 15, 2020
ARID1A determines luminal identity and therapeutic response in estrogen-receptor-positive breast cancerGuotai Xu, Sagar Chhangawala, Emiliano Cocco, et al.
Pageof 16

Showing results (151-160 of 155) with videos related to

Sort By:
Pageof 16
You have reached the last page of results.This site can display upto 155 results.
Nature Genetics|November 1, 2001
Mutation of BSND causes Bartter syndrome with sensorineural deafness and kidney failureR Birkenhäger, E Otto, M J Schürmann, et al.
Frontiers in Immunology|February 9, 2026
POLB 001, a p38 MAPK inhibitor, decreases local and systemic inflammatory responses following <i>in vivo</i> LPS administration in healthy volunteers: a randomised, double-blind, placebo-controlled studyDigna T de Bruin, Manon A A Jansen, Diana R Pereira, et al.
Cell Reports|November 2, 2022
Arid1a loss potentiates pancreatic β-cell regeneration through activation of EGF signalingCemre Celen, Jen-Chieh Chuang, Shunli Shen, et al.
Journal of Psychopharmacology (Oxford, England)|October 16, 2025
A novel psychedelic 5-HT<sub>2A</sub> receptor agonist GM-2505: The pharmacokinetic, safety, and pharmacodynamic profile from a randomized trial healthy volunteerGerard J Marek, Soma Makai-Bölöni, Daniel Umbricht, et al.
Nature Genetics|January 15, 2020
ARID1A determines luminal identity and therapeutic response in estrogen-receptor-positive breast cancerGuotai Xu, Sagar Chhangawala, Emiliano Cocco, et al.
Pageof 16